I am not a big advocate of diversification. I like to put most of my eggs in one basket and then I carefully watch the basket.
For the last several years, I have had the lions' share of my liquid assets in Pfizer, the second-best Dow performer of the new decade that began on Jan. 1, 2011.
While the stock has gained 57.8% the last 25 months, superior options methiods have enabled me to increase the value of my Pfizer portfolio from 262K to 773K, a near triple.
Sentiment: Hold